Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease

被引:13
作者
Yu, Xianfeng [1 ]
Shao, Kai [1 ]
Wan, Ke [2 ]
Li, Taoran [1 ]
Li, Yuxia [3 ]
Zhu, Xiaoqun [2 ]
Han, Ying [1 ,4 ,5 ,6 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China
[2] Anhui Med Univ, Affiliated Hosp 1, Dept Neurol, Hefei 230022, Anhui, Peoples R China
[3] Tangshan Cent Hosp, Dept Neurol, Tangshan 063000, Hebei, Peoples R China
[4] Hainan Univ, Sch Biomed Engn, Haikou 570228, Hainan, Peoples R China
[5] Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Beijing 100053, Peoples R China
[6] Natl Clin Res Ctr Geriatr Dis, Beijing 100053, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; Biomarker; Blood; Evolving technologies; Subjective cognitive decline; NEUROFILAMENT LIGHT-CHAIN; PLASMA TAU; DEMENTIA; ASSOCIATION; RISK; NEURODEGENERATION; INDIVIDUALS; IMPAIRMENT; DIAGNOSIS; FRAMEWORK;
D O I
10.1097/CM9.0000000000002566
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disease that gradually impairs cognitive functions. Recently, there has been a conceptual shift toward AD to view the disease as a continuum. Since AD is currently incurable, effective intervention to delay or prevent pathological cognitive decline may best target the early stages of symptomatic disease, such as subjective cognitive decline (SCD), in which cognitive function remains relatively intact. Diagnostic methods for identifying AD, such as cerebrospinal fluid biomarkers and positron emission tomography, are invasive and expensive. Therefore, it is imperative to develop blood biomarkers that are sensitive, less invasive, easier to access, and more cost effective for AD diagnosis. This review aimed to summarize the current data on whether individuals with SCD differ reliably and effectively in subjective and objective performances compared to cognitively normal elderly individuals, and to find one or more convenient and accessible blood biomarkers so that researchers can identify SCD patients with preclinical AD in the population as soon as possible. Owing to the heterogeneity and complicated pathogenesis of AD, it is difficult to make reliable diagnoses using only a single blood marker. This review provides an overview of the progress achieved to date with the use of SCD blood biomarkers in patients with preclinical AD, highlighting the key areas of application and current challenges.
引用
收藏
页码:505 / 521
页数:17
相关论文
共 92 条
[1]   Plasma Lipids as Biomarxers for Alzheimer's Disease: A Systematic Review [J].
Agarwal, Mehak ;
Khan, Safeera .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
[2]   Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease [J].
Alawode, D. O. T. ;
Heslegrave, A. J. ;
Ashton, N. J. ;
Karikari, T. K. ;
Simren, J. ;
Montoliu-Gaya, L. ;
Pannee, J. ;
O'Connor, A. ;
Weston, P. S. J. ;
Lantero-Rodriguez, J. ;
Keshavan, A. ;
Snellman, A. ;
Gobom, J. ;
Paterson, R. W. ;
Schott, J. M. ;
Blennow, K. ;
Fox, N. C. ;
Zetterberg, H. .
JOURNAL OF INTERNAL MEDICINE, 2021, 290 (03) :583-601
[3]  
Andreasson Ulf, 2016, Alzheimers Dement (Amst), V3, P98, DOI 10.1016/j.dadm.2016.05.005
[4]  
[Anonymous], 2021, World Alzheimer report 2021: journey through the diagnosis of dementia
[5]   Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology [J].
Ashton, Nicholas J. ;
Pascoal, Tharick A. ;
Karikari, Thomas K. ;
Benedet, Andrea L. ;
Lantero-Rodriguez, Juan ;
Brinkmalm, Gunnar ;
Snellman, Anniina ;
Scholl, Michael ;
Troakes, Claire ;
Hye, Abdul ;
Gauthier, Serge ;
Vanmechelen, Eugeen ;
Zetterberg, Henrik ;
Rosa-Neto, Pedro ;
Blennow, Kaj .
ACTA NEUROPATHOLOGICA, 2021, 141 (05) :709-724
[6]   Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study [J].
Baldacci, Filippo ;
Lista, Simone ;
Manca, Maria Laura ;
Chiesa, Patrizia A. ;
Cavedo, Enrica ;
Lemercier, Pablo ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Habert, Marie-Odile ;
Potier, Marie Claude ;
Dubois, Bruno ;
Vergallo, Andrea ;
Hampel, Harald .
ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)
[7]   Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI [J].
Bangen, Katherine J. ;
Thomas, Kelsey R. ;
Weigand, Alexandra J. ;
Edmonds, Emily C. ;
Clark, Alexandra L. ;
Solders, Seraphina ;
Delano-Wood, Lisa ;
Galasko, Douglas R. ;
Bondi, Mark W. .
ALZHEIMERS & DEMENTIA, 2021, 17 (10) :1756-1762
[8]   Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases [J].
Barbagallo, Cristina ;
Mostile, Giovanni ;
Baglieri, Gloriangela ;
Giunta, Flavia ;
Luca, Antonina ;
Raciti, Loredana ;
Zappia, Mario ;
Purrello, Michele ;
Ragusa, Marco ;
Nicoletti, Alessandra .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 2020, 40 (04) :531-546
[9]   Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease [J].
Bergland, Anne Katrine ;
Proitsi, Petroula ;
Kirsebom, Bjorn-Eivind ;
Soennesyn, Hogne ;
Hye, Abdul ;
Larsen, Alf Inge ;
Xu, Jin ;
Legido-Quigley, Cristina ;
Rajendran, Lawrence ;
Fladby, Tormod ;
Aarsland, Dag .
JOURNAL OF ALZHEIMERS DISEASE, 2020, 77 (03) :1117-1127
[10]   Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants [J].
Chatterjee, Pratishtha ;
Goozee, Kathryn ;
Sohrabi, Hamid R. ;
Shen, Kaikai ;
Shah, Tejal ;
Asih, Prita R. ;
Dave, Preeti ;
ManYan, Candice ;
Taddei, Kevin ;
Chung, Roger ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Martins, Ralph N. .
JOURNAL OF ALZHEIMERS DISEASE, 2018, 63 (02) :479-487